Exploitation of a Very Small Peptide Nucleic Acid As a New Inhibitor of MiR-509-3p Involved in the Regulation of Cystic Fibrosis Disease-gene Expression

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 May 16

PMID 24829907

Citations 24

Authors

Felice Amato

Rossella Tomaiuolo

Fabrizia Nici

Nicola Borbone

Ausilia Elce

Bruno Catalanotti

Stefano DErrico

Carmine Marco Morgillo

Giuseppe De Rosa

Laura Mayol

Gennaro Piccialli

Giorgia Oliviero

Giuseppe Castaldo

Affiliations

Soon will be listed here.

Abstract

Computational techniques, and in particular molecular dynamics (MD) simulations, have been successfully used as a complementary technique to predict and analyse the structural behaviour of nucleic acids, including peptide nucleic acid- (PNA-) RNA hybrids. This study shows that a 7-base long PNA complementary to the seed region of miR-509-3p, one of the miRNAs involved in the posttranscriptional regulation of the CFTR disease-gene of Cystic Fibrosis, and bearing suitable functionalization at its N- and C-ends aimed at improving its resistance to nucleases and cellular uptake, is able to revert the expression of the luciferase gene containing the 3'UTR of the gene in A549 human lung cancer cells, in agreement with the MD results that pointed at the formation of a stable RNA/PNA heteroduplex notwithstanding the short sequence of the latter. The here reported results widen the interest towards the use of small PNAs as effective anti-miRNA agents.

Citing Articles

Perspectives in MicroRNA Therapeutics for Cystic Fibrosis.

Finotti A, Gambari R Noncoding RNA. 2025; 11(1.

PMID: 39846681 PMC: 11755495. DOI: 10.3390/ncrna11010003.

Exploring the DNA-PNA heterotriplex formation in targeting the Bcl-2 gene promoter: A structural insight by physico-chemical and microsecond-scale MD investigation.

Falanga A, Lupia A, Tripodi L, Morgillo C, Moraca F, Roviello G Heliyon. 2024; 10(3):e24599.

PMID: 38317891 PMC: 10839560. DOI: 10.1016/j.heliyon.2024.e24599.

Nanocarrier-Mediated Delivery of MicroRNAs for Fibrotic Diseases.

Guo Y, Wang H, Lyu R, Wang J, Wang T, Shi J Mol Diagn Ther. 2023; 28(1):53-67.

PMID: 37897655 DOI: 10.1007/s40291-023-00681-y.

Use of adenine base editing and homology-independent targeted integration strategies to correct the cystic fibrosis causing variant, W1282X.

Mention K, Cavusoglu-Doran K, Joynt A, Santos L, Sanz D, Eastman A Hum Mol Genet. 2023; 32(23):3237-3248.

PMID: 37649273 PMC: 10656707. DOI: 10.1093/hmg/ddad143.

Combined Treatment of Bronchial Epithelial Calu-3 Cells with Peptide Nucleic Acids Targeting miR-145-5p and miR-101-3p: Synergistic Enhancement of the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator ( Gene.

Papi C, Gasparello J, Zurlo M, Manicardi A, Corradini R, Cabrini G Int J Mol Sci. 2022; 23(16).

PMID: 36012615 PMC: 9409490. DOI: 10.3390/ijms23169348.

References

Amato J, Stellato M, Pizzo E, Petraccone L, Oliviero G, Borbone N . PNA as a potential modulator of COL7A1 gene expression in dominant dystrophic epidermolysis bullosa: a physico-chemical study. Mol Biosyst. 2013; 9(12):3166-74. DOI: 10.1039/c3mb70283a. View

Rodriguez A, Vigorito E, Clare S, Warren M, Couttet P, Soond D . Requirement of bic/microRNA-155 for normal immune function. Science. 2007; 316(5824):608-11. PMC: 2610435. DOI: 10.1126/science.1139253. View

Castaldo G, Lembo F, Tomaiuolo R . Molecular diagnostics: between chips and customized medicine. Clin Chem Lab Med. 2010; 48(7):973-82. DOI: 10.1515/CCLM.2010.182. View

Craft Jr J, Legge G . An AMBER/DYANA/MOLMOL phosphorylated amino acid library set and incorporation into NMR structure calculations. J Biomol NMR. 2005; 33(1):15-24. DOI: 10.1007/s10858-005-1199-0. View

Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J . Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell. 2005; 120(5):623-34. DOI: 10.1016/j.cell.2004.12.038. View

Amato J, Oliviero G, De Pauw E, Gabelica V . Hybridization of short complementary PNAs to G-quadruplex forming oligonucleotides: An electrospray mass spectrometry study. Biopolymers. 2008; 91(4):244-55. DOI: 10.1002/bip.21124. View

Lanford R, Hildebrandt-Eriksen E, Petri A, Persson R, Lindow M, Munk M . Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2009; 327(5962):198-201. PMC: 3436126. DOI: 10.1126/science.1178178. View

Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C . Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins. 2006; 65(3):712-25. PMC: 4805110. DOI: 10.1002/prot.21123. View

Brognara E, Fabbri E, Aimi F, Manicardi A, Bianchi N, Finotti A . Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. Int J Oncol. 2012; 41(6):2119-27. DOI: 10.3892/ijo.2012.1632. View

10.

Esau C, Davis S, Murray S, Yu X, Pandey S, Pear M . miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006; 3(2):87-98. DOI: 10.1016/j.cmet.2006.01.005. View

11.

Ullah S, John P, Bhatti A . MicroRNAs with a role in gene regulation and in human diseases. Mol Biol Rep. 2013; 41(1):225-32. DOI: 10.1007/s11033-013-2855-1. View

12.

Li Y, Kowdley K . MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics. 2012; 10(5):246-53. PMC: 3611977. DOI: 10.1016/j.gpb.2012.07.005. View

13.

Amato J, Pagano B, Borbone N, Oliviero G, Gabelica V, De Pauw E . Targeting G-quadruplex structure in the human c-Kit promoter with short PNA sequences. Bioconjug Chem. 2011; 22(4):654-63. DOI: 10.1021/bc100444v. View

14.

Brown S, Thomson S, Veal J, Davis D . NMR solution structure of a peptide nucleic acid complexed with RNA. Science. 1994; 265(5173):777-80. DOI: 10.1126/science.7519361. View

15.

Egholm M, Buchardt O, Christensen L, Behrens C, Freier S, Driver D . PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature. 1993; 365(6446):566-8. DOI: 10.1038/365566a0. View

16.

Van Rooij E, Purcell A, Levin A . Developing microRNA therapeutics. Circ Res. 2012; 110(3):496-507. DOI: 10.1161/CIRCRESAHA.111.247916. View

17.

Pooga M, Land T, Bartfai T, Langel U . PNA oligomers as tools for specific modulation of gene expression. Biomol Eng. 2001; 17(6):183-92. DOI: 10.1016/s1389-0344(01)00075-2. View

18.

Nielsen P, Egholm M, Berg R, Buchardt O . Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science. 1991; 254(5037):1497-500. DOI: 10.1126/science.1962210. View

19.

Van Rooij E, Olson E . MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012; 11(11):860-72. PMC: 6813819. DOI: 10.1038/nrd3864. View

20.

Humphrey W, Dalke A, Schulten K . VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33-8, 27-8. DOI: 10.1016/0263-7855(96)00018-5. View